JPWO2020071554A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020071554A5 JPWO2020071554A5 JP2020551131A JP2020551131A JPWO2020071554A5 JP WO2020071554 A5 JPWO2020071554 A5 JP WO2020071554A5 JP 2020551131 A JP2020551131 A JP 2020551131A JP 2020551131 A JP2020551131 A JP 2020551131A JP WO2020071554 A5 JPWO2020071554 A5 JP WO2020071554A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- antigen
- dnajb8
- fam83b
- boris
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024067659A JP2024144409A (ja) | 2018-10-05 | 2024-04-18 | がん幹細胞特異的抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018189834 | 2018-10-05 | ||
| JP2018189834 | 2018-10-05 | ||
| PCT/JP2019/039400 WO2020071554A1 (ja) | 2018-10-05 | 2019-10-04 | がん幹細胞特異的抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024067659A Division JP2024144409A (ja) | 2018-10-05 | 2024-04-18 | がん幹細胞特異的抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2020071554A1 JPWO2020071554A1 (ja) | 2021-09-09 |
| JPWO2020071554A5 true JPWO2020071554A5 (enExample) | 2022-10-14 |
Family
ID=70055296
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551131A Pending JPWO2020071554A1 (ja) | 2018-10-05 | 2019-10-04 | がん幹細胞特異的抗体 |
| JP2024067659A Pending JP2024144409A (ja) | 2018-10-05 | 2024-04-18 | がん幹細胞特異的抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024067659A Pending JP2024144409A (ja) | 2018-10-05 | 2024-04-18 | がん幹細胞特異的抗体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220033513A1 (enExample) |
| EP (1) | EP3862366A4 (enExample) |
| JP (2) | JPWO2020071554A1 (enExample) |
| WO (1) | WO2020071554A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240344030A1 (en) * | 2021-07-28 | 2024-10-17 | Cartesian Therapeutics, Inc. | Multiprotein-engineered cells secreting a multispecific antibody |
| WO2023204290A1 (ja) * | 2022-04-21 | 2023-10-26 | 愛知県 | 多重特異性ナノ粒子 |
| WO2025047920A1 (ja) * | 2023-09-01 | 2025-03-06 | 小野薬品工業株式会社 | Ｈｌａ／がん抗原ｐｖｔ１由来ペプチド複合体特異的抗体 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5728999A (en) * | 1998-07-28 | 2000-02-21 | Micromet Ag | Heterominibodies |
| CN104971341B (zh) * | 2008-10-27 | 2019-12-13 | 北海道公立大学法人札幌医科大学 | 肿瘤干细胞分子标记 |
| CN107586340B (zh) * | 2011-08-23 | 2022-01-21 | 罗切格利卡特公司 | 对t细胞活化性抗原和肿瘤抗原特异性的双特异性抗体及使用方法 |
| US10351626B2 (en) * | 2013-03-14 | 2019-07-16 | The Scripps Research Institute | Targeting agent antibody conjugates and uses thereof |
| BR112015022978A8 (pt) * | 2013-03-15 | 2018-01-23 | Memorial Sloan Kettering Cancer Center | tecnologias de multimerização |
| WO2015050259A1 (ja) * | 2013-10-03 | 2015-04-09 | 大日本住友製薬株式会社 | 腫瘍抗原ペプチド |
| TWI711633B (zh) * | 2014-09-24 | 2020-12-01 | 北海道公立大學法人札幌醫科大學 | 腫瘤抗原胜肽 |
-
2019
- 2019-10-04 US US17/279,965 patent/US20220033513A1/en active Pending
- 2019-10-04 JP JP2020551131A patent/JPWO2020071554A1/ja active Pending
- 2019-10-04 EP EP19870017.1A patent/EP3862366A4/en active Pending
- 2019-10-04 WO PCT/JP2019/039400 patent/WO2020071554A1/ja not_active Ceased
-
2024
- 2024-04-18 JP JP2024067659A patent/JP2024144409A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7209464B2 (ja) | ヒトインターロイキン－２に対する免疫刺激性モノクローナル抗体 | |
| EP1136556B1 (en) | Method of producing multivalent antigen-binding proteins | |
| FI3707159T3 (fi) | Uusia muokattuja t-solureseptoreita ja niitä käyttävä immuuniterapia | |
| JP2019522490A5 (enExample) | ||
| JP2021159081A5 (enExample) | ||
| JP2020500510A5 (enExample) | ||
| JP2019531704A5 (enExample) | ||
| RU2015144098A (ru) | Четырехвалентные биспецифические антитела | |
| JP2012518425A5 (enExample) | ||
| JP2016053091A5 (enExample) | ||
| JP2018502572A5 (enExample) | ||
| JP2020524510A5 (enExample) | ||
| JP2020505919A5 (enExample) | ||
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| JPWO2020077257A5 (enExample) | ||
| JPWO2020071554A5 (enExample) | ||
| CA3008440A1 (en) | Combination therapy comprising a superagonistic antibody against interleukin-2 and a checkpoint blockade agent | |
| CN113646328A (zh) | 一种免疫细胞因子及其制备与用途 | |
| JP2026004299A5 (enExample) | ||
| CN118063620A (zh) | 双特异性抗体 | |
| JPWO2022133169A5 (enExample) | ||
| JP2016529213A5 (enExample) | ||
| WO2021112676A3 (en) | Methods and means for attracting immune effector cells to tumor cells | |
| WO2019192493A1 (zh) | 抗人lag-3单克隆抗体及其应用 | |
| CA2967778A1 (en) | Anti-thyroglobulin t cell receptors |